In Vivo Anti-HIV Activity of the Heparin-Activated Serine Protease Inhibitor Antithrombin III Encapsulated in Lymph-Targeting Immunoliposomes

PLoS ONE

Volumn 7, Issue 11, 2012, Pages

  Asmal, Mohammed ^a,b   Whitney, James B ^a,b   Luedemann, Corinne ^a,b   Carville, Angela ^b   Steen, Robert ^b,c   Letvin, Norman L ^a,b   Geiben Lynn, Ralf ^a,b,d  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c Biopolymers Facility   (United States)

^d Acceleration BioPharmaceuticals Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTITHROMBIN III; HEPARIN; HLA DR ANTIGEN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IMMUNOLIPOSOME; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PROSTAGLANDIN SYNTHASE; PROSTAGLANDIN SYNTHETASE 2; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIVIRAL ACTIVITY; ANTIVIRAL RESISTANCE; ARTICLE; CD4+ T LYMPHOCYTE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY TEST; DOWN REGULATION; DRUG EFFECT; DRUG EFFICACY; DRUG SCREENING; DRUG STABILITY; DRUG TARGETING; ENCAPSULATION; FEMALE; GENE EXPRESSION PROFILING; GENE REGULATORY NETWORK; GROWTH INHIBITION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IN VIVO STUDY; INNATE IMMUNITY; LIPOSOMAL DELIVERY; MACROPHAGE ACTIVATION; MONOCYTE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; RHESUS MONKEY; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; T LYMPHOCYTE ACTIVATION; TRANSCRIPTION REGULATION; TREATMENT DURATION; VIREMIA; VIRUS CELL INTERACTION; VIRUS ISOLATION; VIRUS LOAD; VIRUS REPLICATION; VIRUS RESISTANCE; VIRUS STRAIN; VIRUS TITRATION;

ANIMALS; ANTITHROMBIN III; CD4-POSITIVE T-LYMPHOCYTES; DISEASE MODELS, ANIMAL; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; HEPARIN; HIV INFECTIONS; LIPOSOMES; LYMPH; MACACA MULATTA; MICE; MICE, INBRED C57BL; MICE, INBRED NOD; MICE, KNOCKOUT; MICE, SCID; SERINE PROTEINASE INHIBITORS; SERPINS; VIRUS REPLICATION;

PRIMATES;

EID: 84868325440     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0048234     Document Type: Article

References (73)

1. Siegfried NL, Van Deventer PJ, Mahomed FA, Rutherford GW (2006) Stavudine, lamivudine and nevirapine combination therapy for treatment of HIV infection and AIDS in adults. Cochrane Database Syst Rev: CD004535.
2. Hecht FM, Wang L, Collier A, Little S, Markowitz M, et al. (2006) A multicenter observational study of the potential benefits of initiating combination antiretroviral therapy during acute HIV infection. J Infect Dis 194: 725-733.
3. Schmutz G, Nelson M, Lutz T, Sheldon J, Bruno R, et al. (2006) Combination of tenofovir and lamivudine versus tenofovir after lamivudine failure for therapy of hepatitis B in HIV-coinfection. AIDS 20: 1951-1954.
4. Bartlett JA, Fath MJ, Demasi R, Hermes A, Quinn J, et al. (2006) An updated systematic overview of triple combination therapy in antiretroviral-naive HIV-infected adults. AIDS 20: 2051-2064.
5. Yeni PG, Hammer SM, Hirsch MS, Saag MS, Schechter M, et al. (2004) Treatment for adult HIV infection: 2004 recommendations of the International AIDS Society-USA Panel. JAMA 292: 251-265.
6. Chung RT, Gale M Jr, Polyak SJ, Lemon SM, Liang TJ, et al. (2008) Mechanisms of action of interferon and ribavirin in chronic hepatitis C: Summary of a workshop. Hepatology 47: 306-320.
7. Opal SM, Esmon CT, (2003) Bench-to-bedside review: functional relationships between coagulation and the innate immune response and their respective roles in the pathogenesis of sepsis. Crit Care 7: 23-38.
8. Feistritzer C, Wiedermann CJ, (2007) Effects of anticoagulant strategies on activation of inflammation and coagulation. Expert Opin Biol Ther 7: 855-870.
9. Whitney JB, Asmal M, Geiben-Lynn R, (2011) Serpin Induced Antiviral Activity of Prostaglandin Synthetase-2 against HIV-1 Replication. PLoS One 6: e18589.
10. Bahgat MM, Blazejewska P, Schughart K, (2011) Inhibition of lung serine proteases in mice: a potentially new approach to control influenza infection. Virol J 8: 27.
11. McNeely TB, Shugars DC, Rosendahl M, Tucker C, Eisenberg SP, et al. (1997) Inhibition of human immunodeficiency virus type 1 infectivity by secretory leukocyte protease inhibitor occurs prior to viral reverse transcription. Blood 90: 1141-1149.
12. Shapiro L, Pott GB, Ralston AH, (2001) Alpha-1-antitrypsin inhibits human immunodeficiency virus type 1. FASEB J 15: 115-122.
13. Hayes VM, Gardiner-Garden M, (2003) Are polymorphic markers within the alpha-1-antitrypsin gene associated with risk of human immunodeficiency virus disease? J Infect Dis 188: 1205-1208.
14. Geiben-Lynn R, Brown N, Walker BD, Luster AD, (2002) Purification of a modified form of bovine antithrombin III as an HIV-1 CD8+ T-cell antiviral factor. J Biol Chem 277: 42352-42357.
15. Geiben-Lynn R, Kursar M, Brown NV, Kerr EL, Luster AD, et al. (2001) Noncytolytic inhibition of X4 virus by bulk CD8(+) cells from human immunodeficiency virus type 1 (HIV-1)-infected persons and HIV-1-specific cytotoxic T lymphocytes is not mediated by beta-chemokines. J Virol 75: 8306-8316.
16. Elmaleh DR, Brown NV, Geiben-Lynn R, (2005) Anti-viral activity of human antithrombin III. Int J Mol Med 16: 191-200.
17. Shugars DC, Sauls DL, Weinberg JB, (1997) Secretory leukocyte protease inhibitor blocks infectivity of primary monocytes and mononuclear cells with both monocytotropic and lymphocytotropic strains of human immunodeficiency virus type I. Oral Dis. 3Suppl 1: S70-72.
18. McNeely TB, Dealy M, Dripps DJ, Orenstein JM, Eisenberg SP, et al. (1995) Secretory leukocyte protease inhibitor: a human saliva protein exhibiting anti-human immunodeficiency virus 1 activity in vitro. J Clin Invest 96: 456-464.
19. Dufresne I, Desormeaux A, Bestman-Smith J, Gourde P, Tremblay MJ, et al. (1999) Targeting lymph nodes with liposomes bearing anti-HLA-DR Fab' fragments. Biochim Biophys Acta 1421: 284-294.
20. Orlans FB, (1997) Ethical decision making about animal experiments. Ethics Behav 7: 163-171.
21. Levy JH, Weisinger A, Ziomek CA, Echelard Y, (2001) Recombinant antithrombin: production and role in cardiovascular disorder. Semin Thromb Hemost 27: 405-416.
22. Li M, Gao F, Mascola JR, Stamatatos L, Polonis VR, et al. (2005) Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies. J Virol 79: 10108-10125.
23. Gallo RC, Salahuddin SZ, Popovic M, Shearer GM, Kaplan M, et al. (1984) Frequent detection and isolation of cytopathic retroviruses (HTLV-III) from patients with AIDS and at risk for AIDS. Science 224: 500-503.
24. Shaw GM, Hahn BH, Arya SK, Groopman JE, Gallo RC, et al. (1984) Molecular characterization of human T-cell leukemia (lymphotropic) virus type III in the acquired immune deficiency syndrome. Science 226: 1165-1171.
25. Montefiori DC, Robinson WE Jr, Schuffman SS, Mitchell WM, (1988) Evaluation of antiviral drugs and neutralizing antibodies to human immunodeficiency virus by a rapid and sensitive microtiter infection assay. J Clin Microbiol 26: 231-235.
26. Montefiori DC (2005) Evaluating neutralizing antibodies against HIV, SIV, and SHIV in luciferase reporter gene assays. Curr Protoc Immunol Chapter 12: Unit 12 11.
27. Drusano GL, Prichard M, Bilello PA, Bilello JA, (1996) Modeling combinations of antiretroviral agents in vitro with integration of pharmacokinetics: guidance in regimen choice for clinical trial evaluation. Antimicrob Agents Chemother 40: 1143-1147.
28. Svarovskaia ES, Barr R, Zhang X, Pais GC, Marchand C, et al. (2004) Azido-containing diketo acid derivatives inhibit human immunodeficiency virus type 1 integrase in vivo and influence the frequency of deletions at two-long-terminal-repeat-circle junctions. J Virol 78: 3210-3222.
29. Cline AN, Bess JW, Piatak M Jr, Lifson JD, (2005) Highly sensitive SIV plasma viral load assay: practical considerations, realistic performance expectations, and application to reverse engineering of vaccines for AIDS. J Med Primatol 34: 303-312.
30. Christianson SW, Greiner DL, Hesselton RA, Leif JH, Wagar EJ, et al. (1997) Enhanced human CD4+ T cell engraftment in beta2-microglobulin-deficient NOD-scid mice. J Immunol 158: 3578-3586.
31. Shafer RW, (2006) Rationale and uses of a public HIV drug-resistance database. J Infect Dis 194Suppl 1: S51-58.
32. Sun Y, Schmitz JE, Acierno PM, Santra S, Subbramanian RA, et al. (2005) Dysfunction of simian immunodeficiency virus/simian human immunodeficiency virus-induced IL-2 expression by central memory CD4+ T lymphocytes. J Immunol 174: 4753-4760.
33. Congote LF, (2006) The C-terminal 26-residue peptide of serpin A1 is an inhibitor of HIV-1. Biochem Biophys Res Commun 343: 617-622.
34. Minnema MC, Chang AC, Jansen PM, Lubbers YT, Pratt BM, et al. (2000) Recombinant human antithrombin III improves survival and attenuates inflammatory responses in baboons lethally challenged with Escherichia coli. Blood 95: 1117-1123.
35. Cozzi E, Simioni P, Boldrin M, Seveso M, Calabrese F, et al. (2005) Effects of long-term administration of high-dose recombinant human antithrombin in immunosuppressed primate recipients of porcine xenografts. Transplantation 80: 1501-1510.
36. Schwartz RS, Bauer KA, Rosenberg RD, Kavanaugh EJ, Davies DC, et al. (1989) Clinical experience with antithrombin III concentrate in treatment of congenital and acquired deficiency of antithrombin. The Antithrombin III Study Group. Am J Med 87: 53S-60S.
37. Collen D, Schetz J, de Cock F, Holmer E, Verstraete M, (1977) Metabolism of antithrombin III (heparin cofactor) in man: effects of venous thrombosis and of heparin administration. Eur J Clin Invest 7: 27-35.
38. Knot EA, de Jong E, ten Cate JW, Iburg AH, Henny CP, et al. (1986) Purified radiolabeled antithrombin III metabolism in three families with hereditary AT III deficiency: application of a three-compartment model. Blood 67: 93-98.
39. Tengborn L, Frohm B, Nilsson LE, Nilsson IM, (1981) Antithrombin III concentrate: its catabolism in health and in antithrombin III deficiency. Scand J Clin Lab Invest 41: 469-477.
40. Desormeaux A, Bergeron MG, (2005) Lymphoid tissue targeting of anti-HIV drugs using liposomes. Methods Enzymol 391: 330-351.
41. Collman R, Balliet JW, Gregory SA, Friedman H, Kolson DL, et al. (1992) An infectious molecular clone of an unusual macrophage-tropic and highly cytopathic strain of human immunodeficiency virus type 1. J Virol 66: 7517-7521.
42. Cheng-Mayer C, Levy JA, (1988) Distinct biological and serological properties of human immunodeficiency viruses from the brain. Ann Neurol 23Suppl: S58-61.
43. Bestman-Smith J, Gourde P, Desormeaux A, Tremblay MJ, Bergeron MG, (2000) Sterically stabilized liposomes bearing anti-HLA-DR antibodies for targeting the primary cellular reservoirs of HIV-1. Biochim Biophys Acta 1468: 161-174.
44. Kovochich M, Marsden MD, Zack JA, (2011) Activation of latent HIV using drug-loaded nanoparticles. PLoS One 6: e18270.
45. Boerman OC, Storm G, Oyen WJ, van Bloois L, van der Meer JW, et al. (1995) Sterically stabilized liposomes labeled with indium-111 to image focal infection. J Nucl Med 36: 1639-1644.
46. Desormeaux A, Bergeron MG, (1998) Liposomes as drug delivery system: a strategic approach for the treatment of HIV infection. J Drug Target 6: 1-15.
47. Mallipeddi R, Rohan LC, (2010) Progress in antiretroviral drug delivery using nanotechnology. Int J Nanomedicine 5: 533-547.
48. Chang WK, Tai YJ, Chiang CH, Hu CS, Hong PD, et al. (2011) The comparison of protein-entrapped liposomes and lipoparticles: preparation, characterization, and efficacy of cellular uptake. Int J Nanomedicine 6: 2403-2417.
49. Ignatius R, Mahnke K, Rivera M, Hong K, Isdell F, et al. (2000) Presentation of proteins encapsulated in sterically stabilized liposomes by dendritic cells initiates CD8(+) T-cell responses in vivo. Blood 96: 3505-3513.
50. Xu Y, Slayter HS, (1994) Immunocytochemical localization of endogenous anti-thrombin III in the vasculature of rat tissues reveals locations of anticoagulantly active heparan sulfate proteoglycans. J Histochem Cytochem 42: 1365-1376.
51. Saif MW, Bona R, Greenberg B, (2001) AIDS and thrombosis: retrospective study of 131 HIV-infected patients. AIDS Patient Care STDS 15: 311-320.
52. Saif MW, Greenberg B, (2001) HIV and thrombosis: a review. AIDS Patient Care STDS 15: 15-24.
53. Potthoff AV, Munch J, Kirchhoff F, Brockmeyer NH, (2007) HIV infection in a patient with alpha-1 antitrypsin deficiency: a detrimental combination? AIDS 21: 2115-2116.
54. Bryan CL, Beard KS, Pott GB, Rahkola J, Gardner EM, et al. (2011) HIV infection is associated with reduced serum alpha-1-antitrypsin concentrations. Clin Invest Med 33: E384-389.
55. Kramer HB, Lavender KJ, Qin L, Stacey AR, Liu MK, et al. (2010) Elevation of intact and proteolytic fragments of acute phase proteins constitutes the earliest systemic antiviral response in HIV-1 infection. PLoS Pathog 6: e1000893.
56. Burgener A, Boutilier J, Wachihi C, Kimani J, Carpenter M, et al. (2008) Identification of differentially expressed proteins in the cervical mucosa of HIV-1-resistant sex workers. J Proteome Res 7: 4446-4454.
57. Asmal M, Seaman M, Lin W, Chung RT, Letvin NL, et al. (2012) Inhibition of HCV by the serpin antithrombin III. Virol J 9: 226.
58. Souter PJ, Thomas S, Hubbard AR, Poole S, Romisch J, et al. (2001) Antithrombin inhibits lipopolysaccharide-induced tissue factor and interleukin-6 production by mononuclear cells, human umbilical vein endothelial cells, and whole blood. Crit Care Med 29: 134-139.
59. O'Reilly MS, Pirie-Shepherd S, Lane WS, Folkman J, (1999) Antiangiogenic activity of the cleaved conformation of the serpin antithrombin. Science 285: 1926-1928.
60. Dunzendorfer S, Kaneider N, Rabensteiner A, Meierhofer C, Reinisch C, et al. (2001) Cell-surface heparan sulfate proteoglycan-mediated regulation of human neutrophil migration by the serpin antithrombin III. Blood 97: 1079-1085.
61. Kaneider NC, Egger P, Dunzendorfer S, Wiedermann CJ, (2001) Syndecan-4 as antithrombin receptor of human neutrophils. Biochem Biophys Res Commun 287: 42-46.
62. Kaneider NC, Reinisch CM, Dunzendorfer S, Romisch J, Wiedermann CJ, (2002) Syndecan-4 mediates antithrombin-induced chemotaxis of human peripheral blood lymphocytes and monocytes. J Cell Sci 115: 227-236.
63. Larsson H, Akerud P, Nordling K, Raub-Segall E, Claesson-Welsh L, et al. (2001) A novel anti-angiogenic form of antithrombin with retained proteinase binding ability and heparin affinity. J Biol Chem 276: 11996-12002.
64. Mackewicz CE, Craik CS, Levy JA, (2003) The CD8+ cell noncytotoxic anti-HIV response can be blocked by protease inhibitors. Proc Natl Acad Sci U S A 100: 3433-3438.
65. Lederman MM, Margolis L, (2008) The lymph node in HIV pathogenesis. Semin Immunol 20: 187-195.
66. Zhou X, Shapiro L, Fellingham G, Willardson BM, Burton GF, (2011) HIV replication in CD4+ T lymphocytes in the presence and absence of follicular dendritic cells: inhibition of replication mediated by alpha-1-antitrypsin through altered IkappaBalpha ubiquitination. J Immunol 186: 3148-3155.
67. Saber AA, Aboolian A, LaRaja RD, Baron H, Hanna K, (2001) HIV/AIDS and the risk of deep vein thrombosis: a study of 45 patients with lower extremity involvement. Am Surg 67: 645-647.
68. Stroud JC, Oltman A, Han A, Bates DL, Chen L, (2009) Structural basis of HIV-1 activation by NF-kappaB-a higher-order complex of p50:RelA bound to the HIV-1 LTR. J Mol Biol 393: 98-112.
69. Kim SE, Lee EO, Yang JH, Kang JH, Suh YH, et al. (2012) 15-deoxy-Delta(12,14)-prostaglandin J(2) inhibits human immunodeficiency virus-1 tat-induced monocyte chemoattractant protein-1/CCL2 production by blocking the extracellular signal-regulated kinase-1/2 signaling pathway independently of peroxisome proliferator-activated receptor-gamma and heme oxygenase-1 in rat hippocampal slices. J Neurosci Res.
70. Condra JH, Schleif WA, Blahy OM, Gabryelski LJ, Graham DJ, et al. (1995) In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors. Nature 374: 569-571.
71. Larder BA, Darby G, Richman DD, (1989) HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy. Science 243: 1731-1734.
72. Otto MJ, Garber S, Winslow DL, Reid CD, Aldrich P, et al. (1993) In vitro isolation and identification of human immunodeficiency virus (HIV) variants with reduced sensitivity to C-2 symmetrical inhibitors of HIV type 1 protease. Proc Natl Acad Sci U S A 90: 7543-7547.
73. Richman D, Shih CK, Lowy I, Rose J, Prodanovich P, et al. (1991) Human immunodeficiency virus type 1 mutants resistant to nonnucleoside inhibitors of reverse transcriptase arise in tissue culture. Proc Natl Acad Sci U S A 88: 11241-11245.